{"id":"W2767506942","doi":"10.1093/neuonc/nox168.022","title":"ACTR-27. COMPLIANCE AND TREATMENT DURATION PREDICT SURVIVAL IN A PHASE 3 EF-14 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Temozolomide; Medicine; Glioblastoma; Internal medicine; Oncology; Progression-free survival; Adjuvant; Clinical trial; Overall survival; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005183016,0.0005313542,0.001042104,0.0002326369,0.000217655,0.0006711748,0.0004618266,0.000785044,0.001813039],"category_scores_gemma":[0.003830345,0.0002758177,0.001957177,0.0004048265,0.0003443977,0.0007357484,0.0003994493,0.00187388,0.0003522213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003918574,"about_ca_system_score_gemma":0.0006385716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006878676,"about_ca_topic_score_gemma":0.001494653,"domain_scores_codex":[0.9980667,0.001339916,0.00008876573,0.000192276,0.0001780363,0.0001343623],"domain_scores_gemma":[0.9965587,0.00133578,0.001144786,0.0002214955,0.000157476,0.0005817181],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7592318,0.004328062,0.1565825,0.0004148145,0.005011149,0.0001457685,0.000151304,0.003571504,0.006361672,0.0001885528,0.002635231,0.06137762],"study_design_scores_gemma":[0.07753759,0.1510371,0.7466454,0.0000968321,0.004787539,0.0004799902,0.0001105307,0.01126179,0.002496764,0.0007782641,0.004684277,0.000083915],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960283,0.002248132,0.0002489397,0.0002488068,0.00005754681,0.00008481993,0.000403701,0.00002206164,0.0006575983],"genre_scores_gemma":[0.9972952,0.0004278031,0.0002855131,0.0001965895,0.00006966159,0.000104681,0.0009660792,0.00001292085,0.0006415695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005183016,"threshold_uncertainty_score":0.02741069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0269714515350125,"score_gpt":0.3109597972464867,"score_spread":0.2839883457114742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}